Capella BioScience
2014
FOUNDED
PRIVATE
STATUS
Early Stage VC
LATEST DEAL TYPE
$9.8M
LATEST DEAL AMOUNT
6
INVESTORS
Description
Developer of monoclonal antibody medicines (mAbs) intended to discover, develop, and commercialize medicines based on mAbs therapeutics. The company's medicines leverage novel technologies to develop therapeutics, enabling researchers to research on the latest medical technology based drugs for oncology and autoimmune disease.
Website
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Biotechnology
Other Industries
Pharmaceuticals
Drug Discovery
Primary Office
- 158-160 North Gower Street
- London NW1 2ND
- England, United Kingdom
Request full access to PitchBook
You’re viewing a free company profile from the PitchBook Platform. To explore Capella BioScience’s full profile, request a free trial.
Capella BioScience Valuation and Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 3. Early Stage VC | 16-Aug-2019 | $9.8M | 000.00 | 000.00 | Completed | Startup |
| 2. Early Stage VC (Series A) | 03-Apr-2016 | 000.00 | 000.00 | 00.00 | Completed | Startup |
| 1. Seed Round | 22-Dec-2014 | $2.35M | $2.35M | Completed | Startup |
Capella BioScience Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|---|---|---|---|---|---|---|---|
| Preference | 0,000,000 | 00.000000 | 00.00 | 00.00 | 00 | 00.00 | 00.000 | |
| A Shares | 0,000,000 | 00.000000 | 00.00 | 00.00 | 00 | 00.00 | 00.000 | |
| Seed | 1,500,000 | $0.001226 | $1.23 | $1.23 | 1x | $1.23 | 19.74% |
Capella BioScience Competitors (6)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| OSE Immunotherapeutics | Corporate Backed or Acquired | Nantes, France | 00 | 000.00 | 0000000000 | 000.00 |
| 0000000 | Formerly PE-Backed | Princeton, NJ | 00 | 00000 | 00000000 | 00000 |
| 00000000 | Venture Capital-Backed | Heidelberg, Germany | 00 | 000.00 | 0000000000 | 000.00 |
| 0000000 0000000 | Venture Capital-Backed | Amsterdam, Netherlands | 00 | 0000 | 00000000000 | 0000 |
| 0000000 0000000000 | Formerly VC-backed | Heidelberg, Germany | 000 | 00000 | 00000000000 | 00000 |
Capella BioScience Investors (6)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Board Seat |
Contact Info |
|---|---|---|---|---|---|---|
| Medicxi | Venture Capital | Minority | 000 0000 | 000000 0 | ||
| Osage University Partners | Venture Capital | Minority | 000 0000 | 000000 0 | ||
| Advent Life Sciences | Venture Capital | Minority | 000 0000 | 000000 0 | ||
| Data Collective | Venture Capital | Minority | 000 0000 | 000000 0 | ||
| Farzad Nazem | Angel (individual) | Minority | 000 0000 | 000000 0 |
Capella BioScience Executive Team (4)
Capella BioScience Board Members (2)
| Name | Representing | Role | Since | Contact Info |
|---|---|---|---|---|
| Steve Holmes Ph.D | Capella BioScience | Founder, Board Member & Chief Operating Officer | 000 0000 | |
| William Harrington MD | Osage Venture Partners | Board Observer | 000 0000 |